Vistagen Therapeutics, Inc.

NasdaqCM:VTGN Stock Report

Market Cap: US$69.6m

Vistagen Therapeutics Past Earnings Performance

Past criteria checks 0/6

Vistagen Therapeutics's earnings have been declining at an average annual rate of -9.8%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 12.5% per year.

Key information

-9.8%

Earnings growth rate

33.7%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate12.5%
Return on equity-42.6%
Net Margin-4,516.6%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

We're Hopeful That Vistagen Therapeutics (NASDAQ:VTGN) Will Use Its Cash Wisely

Nov 15
We're Hopeful That Vistagen Therapeutics (NASDAQ:VTGN) Will Use Its Cash Wisely

VistaGen to proceed with phase 3 anxiety nasal spray trial following interim analysis

Sep 08

VistaGen drops 80% as late-stage study for anxiety therapy fails

Jul 22

Here's Why We're Not Too Worried About VistaGen Therapeutics' (NASDAQ:VTGN) Cash Burn Situation

Apr 10
Here's Why We're Not Too Worried About VistaGen Therapeutics' (NASDAQ:VTGN) Cash Burn Situation

VistaGen Therapeutics added to Russell 2000 Index

Jun 16

VistaGen Therapeutics (NASDAQ:VTGN) Is In A Strong Position To Grow Its Business

Jun 07
VistaGen Therapeutics (NASDAQ:VTGN) Is In A Strong Position To Grow Its Business

VistaGen initiates late-stage trial of PH94B in social anxiety disorder

May 26

VistaGen names new chief commercial officer

May 04

How Does VistaGen Therapeutics' (NASDAQ:VTGN) CEO Salary Compare to Peers?

Feb 16
How Does VistaGen Therapeutics' (NASDAQ:VTGN) CEO Salary Compare to Peers?

VistaGen Therapeutics regains Nasdaq listing compliance

Jan 06

VistaGen Therapeutics slumps in after hours trade on underwritten public offering

Dec 17

Revenue & Expenses Breakdown

How Vistagen Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:VTGN Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241-401730
30 Jun 241-331623
31 Mar 241-291420
31 Dec 231-321322
30 Sep 231-351224
30 Jun 230-461333
31 Mar 230-591544
31 Dec 220-641647
30 Sep 220-651648
30 Jun 221-601645
31 Mar 221-491435
31 Dec 212-621227
30 Sep 211-561123
30 Jun 211-47915
31 Mar 211-42811
31 Dec 201-1679
30 Sep 200-1788
30 Jun 200-19710
31 Mar 200-22813
31 Dec 190-24815
30 Sep 190-26718
30 Jun 190-28819
31 Mar 190-26717
31 Dec 180-24716
30 Sep 180-20712
30 Jun 180-1879
31 Mar 180-1677
31 Dec 170-1476
30 Sep 171-1386
30 Jun 171-1275
31 Mar 171-1275
31 Dec 161-18135
30 Sep 160-19124
30 Jun 160-24144
31 Mar 160-51144
31 Dec 150-4894
30 Sep 150-4683
30 Jun 150-3952
31 Mar 150-1452
31 Dec 140-932
30 Sep 140-833
30 Jun 140-833
31 Mar 140-332

Quality Earnings: VTGN is currently unprofitable.

Growing Profit Margin: VTGN is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: VTGN is unprofitable, and losses have increased over the past 5 years at a rate of 9.8% per year.

Accelerating Growth: Unable to compare VTGN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VTGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: VTGN has a negative Return on Equity (-42.55%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 23:58
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Vistagen Therapeutics, Inc. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Gbolahan Amusa BenzChardan Capital Markets, LLC
Lin TsaiJefferies LLC